FDA approves first COVID-19 vaccine

Katherine Shagoury

August 27, 2021
Towfiqu Barbhuiya/Unsplash

The U.S. Food and Drug Administration (FDA) has approved the first novel coronavirus (COVID-19) vaccination, the Pfizer-BioNTech COVID-19 Vaccine, which will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals ages 16 years and older, according to an announcement made by the agency this week.

Since December 11, 2020, the Pfizer-BioNTech vaccine has been available under emergency use authorization in individuals ages 16 years and older. The authorization was expanded to include those ages 12 through 15 years old on May 10, 2021.

While the vaccine is fully approved for individuals ages 16 years and older, the vaccine will continue to be available under emergency use authorization, including for individuals ages 12 through 15, and for the administration of a third dose in certain immunocompromised individuals.

Editor's note: Click here for more information and ongoing COVID-19 updates for integrative healthcare professionals.

About the Author:

Katherine Shagoury

Katherine Shagoury

Katherine Shagoury is the editor of Integrative Practitioner. She brings a decade of experience creating and managing content for national healthcare audiences as a digital editor and professional journalist, including serving as managing editor for a popular medical billing and coding association and as a reporter for the Boston Globe, Boston.com, and USA Today. A certified personal trainer and nutrition coach with the National Academy of Sports Medicine, a certified group fitness instructor with the Athletics and Fitness Association of America, a certified barre instructor, and a TRX qualified trainer, her passion for and commitment to healthy living fuels her enthusiasm for supporting the integrative healthcare community.

© 2024 Diversified Communications. All rights reserved.
Diversified Communications